Jia Q.,Linyi People s Hospital |
Ge X.,Linyi People s Hospital |
Xu Y.,Linyi People s Hospital |
Li C.,Linyi People s Hospital |
Guan B.,Linyi People s Hospital
Journal of Leukemia and Lymphoma | Year: 2011
Objective To compare the effect and toxicity of domestic idarubicin (IDA) and imported daunorubicin (DNR) in the treatment of acute leukemia (AL). Methods According to the random number table method, 68 patients were randomly divided in IDA group with 35 patients and DNR group with 33 patients. In IDA group, the patients with acute myelocytic leukemia were treated following IA scheme (domestic idataubicin plus cytosine arabinoside) and the patients with acute lymphoblastic leukemia were treated following VICLP scheme (vincristine, domestic idataubicin, cyclophosphamide, lasparaginase and prednisone). In DNR group, the patients with acute myelocytic leukemia were treated following DA scheme (imported daunorubicin plus cytosine arabinoside) and the patients with acute lymphoblastic leukemia were treated following VDCLP scheme (vincristine, imported daunorubicin, cyclophosphamide, lasparaginase and prednisone). Results In IDA group, 21 patients achieved a complete remission (CR), 5 patients achieved a partial remission (PR), with a 74.2% (26/35) remission rate (RR). In DNR group, the remission rate was 62.3% (20/33). No differences of the remission rate was found between the two groups (t = 0.89, P = 0.50). 17 patients were found remission over one year in IDA group, and 6 patients were in DNR group. The difference was statistically significant between the two groups (X2 =5.56, P =0.02). Conclusion IDA is more effective than DNR in AL treatment. The higher RR and longer remission time are found in IDA group than DNR group. IDA is effective and safe in the treatment of AL.